Overview

PGL2001 Proof of Concept Study in Symptomatic Endometriosis

Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, multicentre, randomised, two-arm, parallel group ,double-blind, placebo controlled, study to investigate the efficacy, safety, pharmacokinetics and pharmacodynamics of the steroid sulfatase inhibitor PGL2001 with concomitant, continuous NETA administration for the treatment of pain symptoms suggestive of endometriosis. The target population will be women of reproductive age with symptoms suggestive of endometriosis.
Phase:
Phase 2
Details
Lead Sponsor:
PregLem SA
Treatments:
Norethindrone
Norethindrone acetate